Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

First In class oliGo THerapy for Myotonic Dystrophy type 1 (DM1)

Project description

A novel molecular therapy against myotonic dystrophy

Myotonic dystrophy type 1 is an inherited muscular dystrophy that is characterised by muscle weakness and wasting as well as prolonged muscle tensing. Recent evidence indicates altered microRNA expression such as upregulation of the microRNA-23b which plays a key role in the translation of muscle-related proteins. Funded by the European Innovation Council, the fight-dm1 project will bring forward a novel molecular therapy based on synthetic single-stranded oligonucleotides called antimiRs. These molecules have been designed to be complementary to that of microRNA-23b so that they can block its function or degrade it. Following promising preclinical efficacy, the patented technology will be validated in a patient study.

Objective

Myotonic dystrophy type 1 (DM1) is a clinically and genetically heterogeneous disorder with more than 1 million diagnosed patients worldwide, making it the most common adult muscular dystrophy. Available treatments only relief symptoms. Given this need, we offer ATX-01, a first in class miRNA therapy that inhibits miR-23b without changing the DNA, which rescues DM1 pathogenic mis-splicing. We have demonstrated improved target engagement effects in skeletal and respiratory muscle in in-vitro and in-vivo studies, granting us an FDA pre-IND approval and orphan drug designation. Our approach, antimiRs conjugated to fatty acids, constitutes the ENTRY platform, which guarantees efficient drug delivery to target muscular and extra-muscular tissue at low doses. This patented technology will be validated through a Phase I/IIa clinical trial and chronic preclinical studies, to then be extended to applications as other myotonic dystrophies, Fuchs dystrophy, cachexia, among other opportunities.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2022-ACCELERATOR-01

See all projects funded under this call

Coordinator

ARTHEX BIOTECH SL
Net EU contribution
€ 2 500 000,00
Address
CALLE CATEDRATICO AGUSTIN ESCARDINO
46980 Valencia
Spain
SME
Yes
Region
Este Comunitat Valenciana Valencia/València
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 20 074 282,53